Each ampoule contains 1 g of L-carnitine per 5 mL (200 mg/mL).
Used in the treatment of primary carnitine deficiency and in carnitine deficiency secondary to a variety of defects of intermediary metabolism or other conditions such as haemodialysis.
Primary and secondary carnitine deficiency: Myocardial metabolism disorder caused by ischemic heart disease: angina pectoris, acute myocardial infarction.
Adult: 100 mg/kg in 3 to 4 divided doses by slow intravenous injection over 2 to 3 minutes.
Dosage is adjusted on age and severity.
Terminal stage carnitine deficiency in haemodialysis patients: At the beginning step, it is strongly recommended that, before initiating haemodialysis, plasma carnitine is measured and dosage is adjusted. A dose of 10-20 mg per kg should be administered as an intravenous injection over 2-3 minutes at the end of each dialysis session.
Hypersensitivity to any of the constituents of the product.
When ampoules are cut, glass fragments can be mixed and cause side effects. Therefore ampoule should be cut carefully to minimize glass fragment, particularly in the use of the elderly and children.
As safety in human pregnancy has not been established, women who are pregnant or considering pregnancy should be administered only if therapeutic benefits justify the possible risks.
It is not known whether this drug is excreted in human milk or not. However, this drug should be cautiously administered during nursing because many drugs are excreted in human milk.
Transient nausea and vomiting have been observed. Less frequent adverse reactions are body odor, nausea, and gastritis. Seizures have been reported to occur in patients with or without pre existing seizure activity receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.
In double blind, placebo controlled trial for patients with chronic haemodialysis, the following adverse reactions without casual relation to this drug were reported.
Adverse reaction with incidence not less than 5%:
Click on icon to see table/diagram/image
Acenocoumarol interacts with L-CARNITINE: Acenocoumarol is used to slow blood clotting. L-carnitine might increase the effectiveness of acenocoumarol. Increasing the effectiveness of acenocoumarol might slow blood clotting too much, the dose of the patient's acenocoumarol might need to be changed.
Thyroid hormone interacts with L-CARNITINE: L-carnitine seems to decrease how well thyroid hormone works in the body. Taking L-carnitine with thyroid hormone might decrease the effectiveness of the thyroid hormone.
Warfarin interacts with L-CARNITINE: Warfarin is used to slow blood clotting. L-carnitine might increase the effects of warfarin and increase the chances of bruising and bleeding. The patient's blood should be checked regularly. The dose of the patient's warfarin might need to be changed.
Store at temperatures not exceeding 30°C.
A16AA01 - levocarnitine ; Belongs to the class of amino acids and derivatives products. Used in treatment of alimentary tract and metabolism problems.
Soln for inj (amp) 200 mg/mL (clear, colorless) x 5 mL x 10's.